"In a 2024 study, we evaluated the diagnostic accuracy of a novel plasma phosphorylated tau 217 immunoassay for detecting Alzheimer disease pathology. Our results demonstrate high sensitivity and specificity, suggesting its potential utility as a non-invasive biomarker for AD diagnosis, thereby informing early intervention and disease monitoring strategies."